InspireMD (NSPR) EBITDA (2010 - 2025)

InspireMD's EBITDA history runs 16 years deep, the most recent figure standing at -$12.1 million for Q4 2025.

• On a quarterly basis, EBITDA fell 29.01% year-over-year to -$12.1 million in Q4 2025; TTM through Dec 2025 was -$49.6 million, a 48.09% decrease from a year earlier, with the FY2025 full-year figure at -$49.6 million, down 48.09% from the prior year.
• EBITDA improved to -$12.1 million in Q4 2025 per NSPR's latest filing, from -$13.1 million in the prior quarter.
• Across five years, EBITDA topped out at -$3.3 million in Q1 2021 and bottomed at -$13.1 million in Q3 2025.
• The 5-year median for EBITDA is -$5.5 million (2023), against an average of -$6.9 million.
• Across the five-year window, EBITDA sank 83.64% in 2021 and increased 2.34% in 2023, its largest moves.
• Year by year, EBITDA stood at -$3.9 million in 2021, then retreated by 25.57% to -$4.9 million in 2022, then dropped by 17.67% to -$5.8 million in 2023, then tumbled by 61.28% to -$9.4 million in 2024, then retreated by 29.01% to -$12.1 million in 2025.
• Per Business Quant, the three latest NSPR EBITDA figures stand at -$12.1 million (Q4 2025), -$13.1 million (Q3 2025), and -$13.0 million (Q2 2025).